2012 EDUCATIONAL BOOK - American Society of Clinical Oncology

663513, a fully human anti-CD137 agonist monoclonal antibody in patients
with advanced cancer. J Clin Oncol. 2008;26;15s (suppl; abstr 3007).
23. Curti BW, Morris N. A phase I trial of monoclonal antibody to OX40 in
patients with advanced cancer (abstract). International Society for Biological
Therapy of Cancer Annual Meeting. 2007.
24. Sabatino MK, Panelli MC. Serum vascular endothelial growth factor
and fibronectin predict clinical response to high-dose interleukin-2 therapy.
J Clin Oncol. 2009;27:2645-2652.
25. Joseph RW, Sullivan RJ, Harrell R, et al. Correlation of NRAS mutations
with clinical response to high-dose IL-2 in patients with advanced
melanoma. J Immunother. 2012;35:66-72.
26. Sullivan RJ, Hoshida Y, Brunet J, et al. A single center experience with
high-dose IL-2 treatment for patients with advanced melanoma and pilot
investigation of a novel gene expression signature as a predictor of response.
J Clin Oncol. 2009;27:15s (suppl; abstr 9003).
27. Gajewski TF, Louahed J, Brichard VG. Gene signature in melanoma
associated with clinical activity: A potential clue to unlock cancer immunotherapy.
Cancer J. 2010;16:399-403.
28. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated
BRAF in metastatic melanoma. N Engl J Med. 2010;363:809-819.
29. Chapman PB, Hauschild A, Robert C, et al. Improved survival with
vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med.
2011;364:2507-2516.
30. Kefford RA, Brown MP, Millward M, et al. Phase I/II study of
GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in
patients with metastatic melanoma and other solid tumors. J Clin Oncol.
2010;28;15s (suppl; abstr 8503).
530
FLAHERTY, SOSMAN, AND ATKINS
31. Ribas AK, Schuchter L, Gonzalez R, et al. BRIM 2: An open-label,
multicenter phase II study of vemurafenib (PLX4032, RG7204) in previously
treated patients with BRAFV600E mutation-positive metastatic melanoma.
J Clin Oncol. 2011;29:15s (abstr; suppl 8509).
32. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamouscell
carcinomas in patients treated with BRAF inhibitors. N Engl J Med.
2012;366:207-215.
33. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to
B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468:
973-977.
34. Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance
to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol.
2011;29:3085-3096.
35. Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to
RAF inhibition through MAP kinase pathway reactivation. Nature. 2010;468:
968-972.
36. Poulikakos PI, Persaud Y, Janakiraman M, et al. RAF inhibitor
resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
Nature. 2011;480:387-390.
37. Villanueva J, Vultur A, Lee JT, et al. Acquired resistance to BRAF
inhibitors mediated by a RAF kinase switch in melanoma can be overcome by
cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010;18:683-695.
38. Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of
imatinib mesylate in patients with metastatic melanoma harboring c-Kit
mutation or amplification. J Clin Oncol. 2011;29:2904-2909.
39. Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic
target in metastatic melanoma. JAMA. 2011;305:2327-2334.